4.72
0.02 (0.43%)
| Previous Close | 4.70 |
| Open | 4.65 |
| Volume | 101,656 |
| Avg. Volume (3M) | 660,373 |
| Market Cap | 175,976,704 |
| Price / Sales | 0.350 |
| Price / Book | 0.550 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2024 - 4 Nov 2024 |
| Profit Margin | -16.54% |
| Operating Margin (TTM) | -15.66% |
| Diluted EPS (TTM) | -1.87 |
| Quarterly Revenue Growth (YOY) | -6.70% |
| Total Debt/Equity (MRQ) | 90.24% |
| Current Ratio (MRQ) | 5.02 |
| Operating Cash Flow (TTM) | -46.96 M |
| Levered Free Cash Flow (TTM) | -24.21 M |
| Return on Assets (TTM) | -9.02% |
| Return on Equity (TTM) | -24.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Nevro Corp. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | 0.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.30 |
|
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 3.66% |
| % Held by Institutions | 102.73% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Palo Alto Investors Lp | 30 Jun 2024 | 750,371 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 7.00 (RBC Capital, 48.31%) | Hold |
| Median | 4.85 (2.75%) | |
| Low | 4.00 (Wells Fargo, -15.25%) | Hold |
| 4.00 (Canaccord Genuity, -15.25%) | Hold | |
| 4.00 (Morgan Stanley, -15.25%) | Sell | |
| Average | 5.09 (7.84%) | |
| Total | 6 Hold, 2 Sell | |
| Avg. Price @ Call | 4.52 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 18 Dec 2024 | 4.70 (-0.42%) | Hold | 3.74 |
| Citigroup | 11 Dec 2024 | 5.00 (5.93%) | Hold | 4.31 |
| Wells Fargo | 11 Dec 2024 | 4.00 (-15.25%) | Hold | 4.31 |
| 03 Dec 2024 | 5.00 (5.93%) | Hold | 4.26 | |
| Canaccord Genuity | 09 Dec 2024 | 4.00 (-15.25%) | Hold | 4.35 |
| 12 Nov 2024 | 7.00 (48.31%) | Hold | 5.06 | |
| Morgan Stanley | 02 Dec 2024 | 4.00 (-15.25%) | Sell | 4.27 |
| Baird | 12 Nov 2024 | 6.00 (27.12%) | Hold | 5.06 |
| Piper Sandler | 12 Nov 2024 | 6.00 (27.12%) | Sell | 5.06 |
| RBC Capital | 12 Nov 2024 | 7.00 (48.31%) | Hold | 5.06 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| RASHID KASHIF | - | 3.71 | -527 | -1,955 |
| Aggregate Net Quantity | -527 | |||
| Aggregate Net Value ($) | -1,955 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 3.71 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RASHID KASHIF | Officer | 04 Jan 2025 | Disposed (-) | 527 | 3.71 | 1,955 |
| Date | Type | Details |
|---|---|---|
| 13 Jan 2025 | Announcement | Nevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue Results |
| 17 Dec 2024 | Announcement | Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 |
| 18 Nov 2024 | Announcement | New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches |
| 15 Nov 2024 | Announcement | Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 |
| 12 Nov 2024 | Announcement | Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally |
| 11 Nov 2024 | Announcement | Nevro Reports Third-Quarter 2024 Financial Results |
| 29 Oct 2024 | Announcement | New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy |
| 16 Oct 2024 | Announcement | Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |